Outcomes of endovascular treatment for infrapopliteal peripheral artery disease based on the updated TASC II classification

Arne M. Müller, Veronika Räpple, Christian Bradaric, Tobias Koppara, Victoria Kehl, Massimiliano Fusaro, Salvatore Cassese, Ilka Ott, Adnan Kastrati, Karl Ludwig Laugwitz, Tareq Ibrahim

Research output: Contribution to journalArticlepeer-review

9 Scopus citations

Abstract

We retrospectively analyzed all endovascular procedures of infrapopliteal arterial lesions (n = 383) performed in 270 patients at our institution between December 2008 and January 2018. The overall technical success rate was 97% and yielded 98% for stenoses (n = 214) and 95% for occlusions (n = 169). Trans-Atlantic Inter-Society Consensus (TASC II) classification had no impact on success rates (TASC A + B vs C + D; 96.5% vs 96.9%, p = 0.837). Freedom from clinically driven target lesion revascularization (TLR) after 6 and 12 months was 88.3% and 77.2%. TLR was comparable for TASC A to C lesions and no difference was observed comparing groups of moderately complex TASC A/B lesions and more complex TASC C/D lesions (TASC A + B vs C + D; 78.5% vs 74.2%, p = 0.457). Freedom from TLR was significantly lower in very complex TASC D lesions (TASC A + B + C vs D; 79.7% vs 42.5%, p < 0.001). Multivariate analysis identified TASC D lesions (hazard ratio D/A: 1.5; overall p = 0.002), Fontaine class III and IV (hazard ratio III or IV/IIa or IIb: 2.4; p = 0.041), and occlusive lesions (hazard ratio occlusion/stenosis: 2.4; p = 0.026) as predictors for TLR. In conclusion, endovascular therapy for infrapopliteal artery disease was safe and accompanied with a promising long-term outcome.

Original languageEnglish
Pages (from-to)18-25
Number of pages8
JournalVascular Medicine
Volume26
Issue number1
DOIs
StatePublished - Feb 2021

Keywords

  • angioplasty
  • atherosclerosis
  • endovascular procedures
  • infrapopliteal arteries
  • peripheral artery disease (PAD)

Fingerprint

Dive into the research topics of 'Outcomes of endovascular treatment for infrapopliteal peripheral artery disease based on the updated TASC II classification'. Together they form a unique fingerprint.

Cite this